Literature DB >> 26630551

Resolvin D1 attenuates CCl4-induced acute liver injury involving up-regulation of HO-1 in mice.

Xiahong Chen1, Xia Gong2, Rong Jiang3, Bin Wang4, Ge Kuang1, Ke Li5, Jingyuan Wan1.   

Abstract

Acute hepatic failure involves in excessive oxidative stress and inflammatory responses, leading to a high mortality due to lacking effective therapy. Resolvin D1 (RvD1), an endogenous lipid mediator derived from polyunsaturated fatty acids, has been shown anti-inflammatory and anti-oxidative actions, however, whether RvD1 has protective effects on hepatic failure remains elusive. In this study, the roles and molecular mechanisms of RvD1 were explored in carbon tetrachloride (CCl4)-induced acute liver injury. Our results showed that RvD1 protected mice against CCl4-induced hepatic damage, as evaluated by reduced aminotransferase activities and malondialdehyde content, elevated glutathione and superoxide dismutase activities, and alleviated hepatic pathological damage. Moreover, RvD1 significantly attenuated serum tumor necrosis factor-α and interleukin-6 levels as well as hepatic myeloperoxidase activity, whereas enhanced serum IL-10 level in CCl4-administered mice. Further, RvD1 markedly up-regulated the expression and activity of heme oxygenase-1 (HO-1). However, inhibition of HO-1 activity reversed the protective effects of RvD1 on CCl4-induced liver injury. These results suggest that RvD1 could effectively prevent CCl4-induced liver injury by inhibition of oxidative stress and inflammation, and the underlying mechanism may be related to up-regulation of HO-1.

Entities:  

Keywords:  Acute liver injury; anti-inflammatory; carbon tetrachloride (CCl4); heme oxygenase-1 (HO-1); resolvin D1 (RvD1)

Mesh:

Substances:

Year:  2015        PMID: 26630551     DOI: 10.3109/08923973.2015.1115517

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  9 in total

1.  Resolvin D1 inhibits the proliferation of lipopolysaccharide-treated HepG2 hepatoblastoma and PLC/PRF/5 hepatocellular carcinoma cells by targeting the MAPK pathway.

Authors:  You Lu; Qingyu Xu; Guowen Yin; Weidong Xu; Hao Jiang
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

2.  Protective effects of honey and bee venom against lipopolysaccharide and carbon tetrachloride-induced hepatoxicity and lipid peroxidation in rats.

Authors:  Noha M Meligi; Suzan Alaa Ismail; Nagy S Tawfik
Journal:  Toxicol Res (Camb)       Date:  2020-10-15       Impact factor: 3.524

3.  SIRT6 Activator UBCS039 Inhibits Thioacetamide-Induced Hepatic Injury In Vitro and In Vivo.

Authors:  Fangzhou Jiao; Zongwei Zhang; Hongtu Hu; Yongxi Zhang; Yong Xiong
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

4.  The Lipid Mediator Resolvin D1 Reduces the Skin Inflammation and Oxidative Stress Induced by UV Irradiation in Hairless Mice.

Authors:  Priscila Saito; Cristina P B Melo; Renata M Martinez; Victor Fattori; Talita L C Cezar; Ingrid C Pinto; Allan J C Bussmann; Josiane A Vignoli; Sandra R Georgetti; Marcela M Baracat; Waldiceu A Verri; Rubia Casagrande
Journal:  Front Pharmacol       Date:  2018-10-31       Impact factor: 5.810

5.  PKCδ Mediates NF-κB Inflammatory Response and Downregulates SIRT1 Expression in Liver Fibrosis.

Authors:  Su Jin Lee; Su Ji Kim; Hyun-Shik Lee; Oh-Shin Kwon
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

6.  Resolvin D1 attenuates CCl4 Induced Liver Fibrosis by Inhibiting Autophagy-Mediated HSC activation via AKT/mTOR Pathway.

Authors:  Jiahuan Li; Xiaoling Deng; Shuhan Wang; Qianqian Jiang; Keshu Xu
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

Review 7.  Lipids in Liver Failure Syndromes: A Focus on Eicosanoids, Specialized Pro-Resolving Lipid Mediators and Lysophospholipids.

Authors:  Florent Artru; Mark J W McPhail; Evangelos Triantafyllou; Francesca Maria Trovato
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

8.  Antioxidant activities of anastatin A & B derivatives and compound 38c's protective effect in a mouse model of CCl4-induced acute liver injury.

Authors:  Cen Xiang; Menglin Cao; Ai Miao; Feng Gao; Xuzhe Li; Guojun Pan; Wenqiang Zhang; Yongmin Zhang; Peng Yu; Yuou Teng
Journal:  RSC Adv       Date:  2020-04-14       Impact factor: 4.036

9.  Breviscapine ameliorates CCl4‑induced liver injury in mice through inhibiting inflammatory apoptotic response and ROS generation.

Authors:  Yu Liu; Pei-Hao Wen; Xin-Xue Zhang; Yang Dai; Qiang He
Journal:  Int J Mol Med       Date:  2018-05-02       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.